Rznomics Inc (KOSDAQ:476830), a South Korea-based biopharmaceutical company specialising in the development of RNA-based gene therapies, announced on Sunday that it is joining Lilly Gateway Labs (LGL) in San Diego, California.

Lilly Gateway Labs is an innovation hub designed to support biotechnology companies by providing access to wet lab facilities and opportunities to engage with scientists and executives from Eli Lilly and Company (NYSE:LLY). Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.

Through its entry into Lilly Gateway Labs, Rznomics says that it plans to accelerate candidate discovery and development across its target gene database bank, comprising over 200 disease targets, while simultaneously driving long-term efforts to establish global clinical infrastructure for its lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the United States.